<DOC>
	<DOCNO>NCT00914095</DOCNO>
	<brief_summary>Therapeutic management gait disorder advance Parkinson 's disease ( PD ) patient sometimes disappointing , since dopaminergic drug treatment subthalamic nucleus ( STN ) stimulation effective limb-related Parkinsonian sign gait disorder . Gait disorder could also partly relate noradrenergic system impairment , pharmacological modulation dopamine noradrenaline pathway could potentially improve symptomatology . The investigator demonstrate use open label study 17 advance PD patient chronic , high dos methylphenidate ( MPD ) improve gait , freeze gait , motor symptom attention absence L-Dopa increase intensity response symptom L-Dopa ( Devos et al. , 2007 ) . The investigator aim confirm result use randomized , double-blind , placebo-controlled , parallel-group , multicentric trial . The investigator assess clinical value chronic , high dos ( 1 mg/kg/day ) MPD v placebo 88 non demented PD patient suffer severe gait disorder freeze despite use optimal dopaminergic dos eventually STN stimulation parameter . Efficacy assess directly video absence L-Dopa acute administration drug , 3-month course MPD , use Stand Walk Sit test ( primary criterion ) , `` Freezing Of Gait trajectory '' , RGSE scale , UPDRS score , dyskinesia rating scale , Achiron scale use auto-questionnaires Giladi , ABC scale PDQ 39 . Attention assess use reaction time . Drowsiness assess use Epworth Parkinson 's disease Sleep Scales . Apathy depression monitor Lille Apathy Rating Scale , MADRS , BPRS , MINI psychiatric interview . Cardiologic general tolerance also monitor . This study could lead propose methylphenidate good efficacy/ risk balance advance PD patient suffer severe gait disorder freeze gait , drowsiness attention deficit .</brief_summary>
	<brief_title>Study Methylphenidate Treat Gait Disorders And Attention Deficit In Parkinson 's Disease ( PARKGAIT-II )</brief_title>
	<detailed_description>Overall study duration : 2 year . Planned inclusion period : 12 month . Study duration individual patient : 4 month 2 week ( 2 week screen randomization , 3 month double-blind treatment 4-week wash-out period ) . Primary objective ( V1 V4 ) : To assess efficacy methylphenidate treatment severe gait disorder include freeze assessed Stand Walk Sit Test patient advance Parkinson 's disease without dementia depression subthalamic stimulation Additional Efficacy Endpoints ( V1 V4 ) : - Gait motor symptom : `` Freezing Of Gait trajectory '' , RGSE scale , UPDRS score ( partI , II , III , IV ) , dyskinesia rating scale - auto-questionnaires Giladi , ABC scale PDQ 39 - Attention : simple complex reaction time - Drowsiness : Epworth Parkinson 's disease Sleep Scales - Apathy Lille Apathy Rating Scale - Depression psychiatric disorder : MADRS , BPRS , MINI psychiatric interview Safety Tolerability Endpoints ( V1 , V2 , V3 V4 ) : Tolerability Number subject ( % ) discontinue study Number subject ( % ) discontinue study due AEs Safety Measures AE incidence Safety laboratory value Vital sign Blood pressure monitor ECG Physical neurological examination Study Design : Multicentric study : 12-week double blind , placebo-controlled phase . After find eligible participate study , subject allocate 1:1 ratio one follow two treatment group base randomization scheme block stratify : one methylphenidate - 1st week : 1/2cp 3 time day ( morning , noon 16h ) - 2nd week : 1cp 3 time day - 3rd week : 1cp + 1/2cp 3 time day - 4th week : depending weight : 2 3 cp 3 time day ( 1 mg/kg/day ) During 2 follow month : 2 3 cp 3 time day ( 1 mg/kg/day ) one placebo 3 month methylphenidate Schedule : 10 visit Six short consultation : screening ( V0 ) , safety visit every 15 day ( V2 , V3 , V4 , V5 , V6 ) two last consultation decrease titration ( V8 , V9 ) Two long visit hospitalization two day : randomization ( V1 , 15 day V0 ) visit termination ( V7 , 3 month randomization ) Patients 76 subject Parkinson 's disease duration 5 year , without dementia ( Mattis Dementia Rating Scale ≥ 130 , MMSE ≥ 27 DSM IV ) , without major depression ( MADRS &lt; 18 ) severe gait disorder include freeze gait ( define answer 2 3 3rd question autoquestionnaire Giladi : Do gait disorder impede daily living activity independence : answer : yes , moderately severely . But patient require physical assistance walk ) despite optimal dopaminergic treatment optimal present stable subthalamic stimulation parameter . No additional therapy permit study . Centres : LILLE : Neurological department , CHU de Lille , EA 2683 , IFR 114 : Pr L. Defebvre , Pr K. Dujardin , Dr D. Devos , Pr Destee , Mme Delliaux . Dr A Kreisler , Dr C Simonin , Dr C. Moreau , Dr A. Delval Department Pharmacology , Faculté de Médecine , Lille II , EA 1046 , IFR 114 : R. Bordet . CHU AMIENS : Pr . P. KRYSTKOWIAK Place Victor PAUCHET - 80054 AMIENS Cedex 1 . CH AIX EN PROVENCE : Dr F. VIALLET Avenue Tamaris - 13616 AIX-en-PROVENCE . APHP - HOPITAL DE LA PITIE SALPETRIERE : Pr M. VIDAILHET 47-83 , Boulevard de l'Hôpital - 75 PARIS 13ème CHU BORDEAUX : Pr . F. TISON 1 , Avenue Magellan - 33600 PESSAC CHU CLERMONT-FERRANT : Pr . F. DURIF 58 , Rue Montalambert - 63000 CLERMONT-FERRRAND CHU CRETEIL : Pr . P. CESARO 51 , Avenue du Maréchal de Lattre de Tassigny - 94000 CRETEIL CHU GRENOBLE : Pr P. POLLAK Bd de la Chantourne - BP 217 - 38700 La Tronche . CHU MARSEILLE : Pr . JP AZULAY Hôpital de la Timone - 13385 MARSEILLE cedex 05 CHU NANTES : Pr PH . DAMIER Hôtel-Dieu - Place Alexis Ricordeau - 44093 Nantes cedex 1 CHU POITIERS : Dr JL HOUETO 2 , Rue de la Milétrie - 86000 POITIERS . CHU RENNES : Pr . M. VERIN CHU Pontchaillou , Rue H. Le Guilloux - 35033 Cedex 9 . CHU ROUEN : DR D. MALTETE 1 , Rue Germont - 76000 ROUEN . CHU TOULOUSE : Pr . O. RASCOL Hôpital Purpan - Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 . CHU STRASBOURG : Pr . C. TRANCHANT Hôpital civil - 1 place de l'hôpital BP 426 - 67091 Strasbourg cedex CHU CAEN : Pr . G. DEFER Avenue Côte de Nacre - 14000 CAEN . CHU NICE : M. BORG Hôpital Pasteur - 30 , Avenue de la Voie Romaine - 06000 NICE Promoteur de l'étude : CHRU de Lille</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Gait Disorders , Neurologic</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Parkinson 's disease 5 year Subthalamic nucleus stimulation Gait disorder impede moderately severely activity daily live gait disorder include freeze gait able walk without physical assistance Dementia ( MMSE &lt; 27 et score de Mattis &lt; 130 ) Requiring dopatherapie modification Requiring subthalamic stimulation parameter adaptation Psychiatric disorder : hallucination , unstable thymic disorder , psychosis ) Cardiac disorder : dysrhythmia unstable arterial hypertension Unstable severe medical illness intolerance contraindication methylphenidate</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Freezing Gait</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Dopamine transporter inhibitor</keyword>
	<keyword>Noradrenaline</keyword>
</DOC>